2026 年 01 月 11 日 北交所研究团队 AI 医疗迎政策红利，北交所成智能诊疗标的布局阵地 ——北交所策略专题报告 诸海滨（分析师） 车欣航（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 截至 2026 年 1 月 9 日，北交所排队企业共 184 家，其中与医药生物领域相关企 业共 15 家，2024 年营收规模均值 4.24 亿元，2024 年净利润规模剔除亏损企业 均值 1.01 亿元，有 2 家为亏损企业。2025 年 12 月 26 日，普昂医疗过会。近期 北交所新受理医药生物企业为延安医药（综合性医药企业）、科州药物（抗肿瘤 等治疗领域小分子创新药物研发）。 风险提示：宏观经济环境变动风险、市场竞争风险、数据统计误差风险。 北 交 所 研 究 北 交 所 策 略 专 题 报 告 相关研究报告 《爱舍伦（920050.BJ）: 医用护理垫、 敷料隐形冠军，深度绑定海外医疗龙 头—北交所新股申购报告》-2026.1.9 《"十五五"医药新机遇：掘金生物制 造与创新主线—北交所策略专题报 告》-2026.1.7 chexinhang@kysec.cn ...

Core Viewpoint - The article highlights the strategic transformation of Wuchan Zhongda Health, focusing on innovation-driven and green transformation in the pharmaceutical and healthcare sector, aiming to integrate medical services with pharmaceutical manufacturing and investment funds [1][5]. Group 1: Company Transformation - Wuchan Zhongda Health is shifting from a primary focus on medical services to a dual approach that includes pharmaceutical manufacturing and investment funds, emphasizing innovation and green transformation [1]. - Hongyuan Pharmaceutical, a subsidiary, has evolved from a traditional chemical factory to a modern green pharmaceutical enterprise, adopting enzyme-catalyzed processes and eliminating traditional chemical synthesis methods [3][4]. Group 2: Environmental Commitment - The company prioritizes ecological responsibility, integrating pollution reduction and safety into its research and development processes, particularly in the production of atorvastatin intermediates [4]. - Hongyuan Pharmaceutical has achieved significant reductions in resource consumption, with steam usage down by 30%, electricity by 17%, and solvents by 40% [4]. Group 3: Investment and Innovation - Wuchan Zhongda Health is integrating innovation platforms with investment funds to break down barriers between research and application, focusing on the pharmaceutical health industry [5][7]. - The company is developing China's first comprehensive solution for Boron Neutron Capture Therapy (BNCT), which has shown promising results in cancer treatment, with a complete response rate of 46% in Japanese patients [5][6]. Group 4: Future Prospects - The pharmaceutical industry fund is seen as a microcosm of Wuchan Zhongda Health's development of new productive forces, accelerating the layout of innovative drugs and medical devices [7]. - The company aims to enhance its independent research capabilities and integrate technological and industrial innovation to contribute to the economic and social development of Zhejiang Province [7].